Alkylating agents: all 3,295 studies that test it

Page 10 of 33. Open to participants first (456), then studies with results posted, then the rest; newest registration first within each.

• Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin LymphomaCompletedNCT01118026Phase 2Results posted
• Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell TransplantTerminatedNCT01118013Phase 2Results posted
• A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma MultiformeCompletedNCT01115491Phase 2Results posted
• Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory NeuroblastomaCompletedNCT01114555Phase 2Results posted
• Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple MyelomaCompletedNCT01110135Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)CompletedNCT01108341Phase 2Results posted
• Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Who Have Undergone SurgeryCompletedNCT01106898Phase 2Results posted
• Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade GliomaTerminatedNCT01105702Phase 2Results posted
• Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic ImbalanceCompletedNCT01100528Phase 2Results posted
• Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL)CompletedNCT01096992Phase 1/2Results posted
• Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed EpendymomaCompletedNCT01096368Phase 3Results posted
• Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01093586Phase 2Results posted
• Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate CancerTerminatedNCT01093183Phase 1/2Results posted
• Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute LeukemiaCompletedNCT01088984Phase 1/2Results posted
• Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) AmyloidosisCompletedNCT01083316Phase 2Results posted
• Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)CompletedNCT01082939Phase 2Results posted
• Lenalidomide and High-Dose MelphalanCompletedNCT01079936Phase 1/2Results posted
• Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain AmyloidosisCompletedNCT01078454Phase 3Results posted
• Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell TransplantTerminatedNCT01078441Phase 2Results posted
• Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)CompletedNCT01073163Phase 3Results posted
• Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain AmyloidosisCompletedNCT01072773Phase 2Results posted
• Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)CompletedNCT01067469Phase 2Results posted
• Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell LeukemiaActive, not recruitingNCT01059786Phase 2Results posted
• A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)CompletedNCT01056510Phase 4Results posted
• Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose ChemotherapyCompletedNCT01056276Phase 2Results posted
• Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic RhabdomyosarcomaCompletedNCT01055314Phase 2Results posted
• Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 StudyActive, not recruitingNCT01054196Phase 1/2Results posted
• Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cellsTerminatedNCT01050764Phase 1/2Results posted
• Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaCompletedNCT01049945Phase 1/2Results posted
• A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent GlioblastomaTerminatedNCT01044966Phase 1/2Results posted
• Allogeneic Bone Marrow Transplant for Inherited Metabolic DisordersCompletedNCT01043640Phase 2Results posted
• Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade LymphomaCompletedNCT01029730Phase 2Results posted
• Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesTerminatedNCT01028716Phase 2Results posted
• Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT01027000Phase 2Results posted
• Veliparib and Temozolomide in Treating Patients With Recurrent GlioblastomaCompletedNCT01026493Phase 1/2Results posted
• Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin LymphomaCompletedNCT01026220Phase 3Results posted
• Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT01024010Phase 2Results posted
• Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast CancerTerminatedNCT01022138Phase 2Results posted
• Whole Brain Radiotherapy With or Without Temozolomide at Daily Fixed-dose for Brain Metastases TreatmentCompletedNCT01015534Phase 2Results posted
• Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus TumorsTerminatedNCT01014767Phase 3Results posted
• Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or GliosarcomaCompletedNCT01013285Phase 2Results posted
• Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) LymphomaCompletedNCT01011920Phase 2Results posted
• Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)TerminatedNCT01010568Phase 2Results posted
• Mismatched Transplantation Using High-dose Post-transplant CyclophosphamideCompletedNCT01010217Phase 2Results posted
• IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma PatientsCompletedNCT01009840Phase 2Results posted
• Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic MelanomaTerminatedNCT01009515Phase 2Results posted
• Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic LeukemiaCompletedNCT01008462Phase 2Results posted
• Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for GlioblastomaCompletedNCT01004874Phase 2Results posted
• Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or GliosarcomaCompletedNCT00998010Phase 2Results posted
• Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure StatesCompletedNCT00997386Phase 2Results posted
• A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic OriginCompletedNCT00993044Phase 1Results posted
• Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & TemozolomideCompletedNCT00990652Phase 2Results posted
• Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell TransplantationCompletedNCT00990249Phase 2Results posted
• Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple MyelomaTerminatedNCT00985907Phase 1/2Results posted
• Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung CancerCompletedNCT00984542Phase 2Results posted
• Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LLTerminatedNCT00981799Phase 1/2Results posted
• Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder CancerCompletedNCT00981656Phase 2Results posted
• Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma MultiformeCompletedNCT00979017Phase 2Results posted
• Haploidentical PBMC Transplant for Severe Congenital AnemiasActive, not recruitingNCT00977691Phase 1/2Results posted
• Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer PatientsTerminatedNCT00974818Phase 3Results posted
• Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLLCompletedNCT00974233Phase 2Results posted
• Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic CancerTerminatedNCT00963872Phase 1/2Results posted
• O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell LymphomaCompletedNCT00961220Phase 1/2Results posted
• Study of Bortezomib in Combination With Cyclophosphamide and RituximabCompletedNCT00958256Phase 2Results posted
• Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity CancerStatus unknownNCT00954174Phase 3Results posted
• Umbilical Cord Blood Transplant for Congenital Pediatric DisordersCompletedNCT00950846Not applicableResults posted
• Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)TerminatedNCT00948389Phase 1/2Results posted
• PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma PatientsCompletedNCT00948090Phase 2Results posted
• Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and RituximabTerminatedNCT00946023Phase 2Results posted
• Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of TestisCompletedNCT00945724Phase 2Results posted
• Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 ExpressionCompletedNCT00944047Phase 2Results posted
• Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic MalignanciesCompletedNCT00943592Phase 1/2Results posted
• Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic MalignanciesCompletedNCT00943319Phase 1/2Results posted
• Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT00941720Phase 2Results posted
• T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)TerminatedNCT00939653Phase 2Results posted
• High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell TumorsCompletedNCT00936936Phase 2Results posted
• PK Study of Melphalan HCL & Alkeran for Injection of MA Conditioning in MM Patients of Autologous TransplantationCompletedNCT00925782Phase 2Results posted
• Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and PanobinostatTerminatedNCT00925132Phase 1/2Results posted
• Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic CancerTerminatedNCT00924287Phase 1/2Results posted
• Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell LeukemiaCompletedNCT00924170Phase 1/2Results posted
• Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMACCompletedNCT00923364Phase 2Results posted
• Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT00920855Phase 1/2Results posted
• Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00918723Phase 1/2Results posted
• Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple MyelomaCompletedNCT00916058Phase 1/2Results posted
• Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHDTerminatedNCT00914940Phase 2Results posted
• Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant MelanomaCompletedNCT00911443Phase 2Results posted
• Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular LymphomaTerminatedNCT00901927Phase 2Results posted
• Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell LymphomaCompletedNCT00891839Phase 2Results posted
• Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia SalvageCompletedNCT00890656Phase 2Results posted
• A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL AmyloidosisCompletedNCT00890552Not applicableResults posted
• Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic MelanomaCompletedNCT00885534Phase 2Results posted
• Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)CompletedNCT00883129Phase 2Results posted
• Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by SurgeryTerminatedNCT00880542Phase 2Results posted
• Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell LymphomaCompletedNCT00878254Phase 2Results posted
• Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT StudyCompletedNCT00877006Phase 3Results posted
• Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) TumorsCompletedNCT00876993Phase 1Results posted
• Capecitabine and Temozolomide for Neuroendocrine CancersCompletedNCT00869050Phase 2Results posted
• Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian CancerCompletedNCT00867503Phase 2Results posted
• Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast CancerCompletedNCT00866905Phase 2Results posted
• Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic LymphomaCompletedNCT00866749Phase 2Results posted

← Alkylating agents overview